Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent plasma for COVID-19 with ARDS
NCT04380935Phase 3Unknown
- Sponsor
- Universitas Indonesia
- Start
- May 2020
- Primary completion
- Oct 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Universitas Indonesia. Primary endpoint: All-cause mortality at 28 days. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04380935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380935.